431 related articles for article (PubMed ID: 29779418)
1. Modeling adverse event counts in phase I clinical trials of a cytotoxic agent.
Muenz DG; Braun TM; Taylor JM
Clin Trials; 2018 Aug; 15(4):386-397. PubMed ID: 29779418
[TBL] [Abstract][Full Text] [Related]
2. A Bayesian dose-finding design for outcomes evaluated with uncertainty.
Schipper MJ; Yuan Y; Taylor JM; Ten Haken RK; Tsien C; Lawrence TS
Clin Trials; 2021 Jun; 18(3):279-285. PubMed ID: 33884907
[TBL] [Abstract][Full Text] [Related]
3. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of irrational dose assignment definitions using the continual reassessment method.
Wages NA; Bagley E
Clin Trials; 2019 Dec; 16(6):665-672. PubMed ID: 31547691
[TBL] [Abstract][Full Text] [Related]
5. Performance of toxicity probability interval based designs in contrast to the continual reassessment method.
Horton BJ; Wages NA; Conaway MR
Stat Med; 2017 Jan; 36(2):291-300. PubMed ID: 27435150
[TBL] [Abstract][Full Text] [Related]
6. Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies.
James GD; Symeonides S; Marshall J; Young J; Clack G
BMC Cancer; 2021 Jan; 21(1):7. PubMed ID: 33402104
[TBL] [Abstract][Full Text] [Related]
7. Dose-finding clinical trial design for ordinal toxicity grades using the continuation ratio model: an extension of the continual reassessment method.
Van Meter EM; Garrett-Mayer E; Bandyopadhyay D
Clin Trials; 2012 Jun; 9(3):303-13. PubMed ID: 22547420
[TBL] [Abstract][Full Text] [Related]
8. Incorporating lower grade toxicity information into dose finding designs.
Iasonos A; Zohar S; O'Quigley J
Clin Trials; 2011 Aug; 8(4):370-9. PubMed ID: 21835856
[TBL] [Abstract][Full Text] [Related]
9. An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles.
Du Y; Yin J; Sargent DJ; Mandrekar SJ
J Biopharm Stat; 2019; 29(2):271-286. PubMed ID: 30403559
[TBL] [Abstract][Full Text] [Related]
10. A nonparametric Bayesian continual reassessment method in single-agent dose-finding studies.
Tang N; Wang S; Ye G
BMC Med Res Methodol; 2018 Dec; 18(1):172. PubMed ID: 30563454
[TBL] [Abstract][Full Text] [Related]
11. Hierarchical models for sharing information across populations in phase I dose-escalation studies.
Cunanan KM; Koopmeiners JS
Stat Methods Med Res; 2018 Nov; 27(11):3447-3459. PubMed ID: 28480828
[TBL] [Abstract][Full Text] [Related]
12. Dose-finding design for multi-drug combinations.
Wages NA; Conaway MR; O'Quigley J
Clin Trials; 2011 Aug; 8(4):380-9. PubMed ID: 21652689
[TBL] [Abstract][Full Text] [Related]
13. A Bayesian dose-finding design incorporating toxicity data from multiple treatment cycles.
Yin J; Qin R; Ezzalfani M; Sargent DJ; Mandrekar SJ
Stat Med; 2017 Jan; 36(1):67-80. PubMed ID: 27633877
[TBL] [Abstract][Full Text] [Related]
14. Comparative review of novel model-assisted designs for phase I clinical trials.
Zhou H; Murray TA; Pan H; Yuan Y
Stat Med; 2018 Jun; 37(14):2208-2222. PubMed ID: 29682777
[TBL] [Abstract][Full Text] [Related]
15. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.
Yin J; Paoletti X; Sargent DJ; Mandrekar SJ
Clin Trials; 2017 Dec; 14(6):611-620. PubMed ID: 28764555
[TBL] [Abstract][Full Text] [Related]
16. Adaptive dose-finding based on safety and feasibility in early-phase clinical trials of adoptive cell immunotherapy.
Wages NA; Fadul CE
Clin Trials; 2020 Apr; 17(2):157-165. PubMed ID: 31856602
[TBL] [Abstract][Full Text] [Related]
17. The 3 + 3 design in dose-finding studies with small sample sizes: Pitfalls and possible remedies.
Chiuzan C; Dehbi HM
Clin Trials; 2024 Jun; 21(3):350-357. PubMed ID: 38618916
[TBL] [Abstract][Full Text] [Related]
18. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
Gerke O; Siedentop H
Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
[TBL] [Abstract][Full Text] [Related]
19. Quasi-partial order continual reassessment method: Applying toxicity scores to cancer dose-finding drug combination trials.
O'Connell NS; Wages NA; Garrett-Mayer E
Contemp Clin Trials; 2023 Feb; 125():107050. PubMed ID: 36529437
[TBL] [Abstract][Full Text] [Related]
20. Incorporating adverse event relatedness into dose-finding clinical trial designs.
Darssan D; Thompson MH; Pettitt AN
Stat Med; 2014 Mar; 33(7):1146-61. PubMed ID: 24122859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
